Citations (81)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
T. V. Radhakrishna Mullapudi, Punna Rao Ravi & Ganapathi Thipparapu. (2021) UGT1A1 and UGT1A3 activity and inhibition in human liver and intestinal microsomes and a recombinant UGT system under similar assay conditions using selective substrates and inhibitors. Xenobiotica 51:11, pages 1236-1246.
Read now
Read now
Saeed Alqahtani, Ishfaq Bukhari, Ahmed Albassam & Maha Alenazi. (2018) An update on the potential role of intestinal first-pass metabolism for the prediction of drug–drug interactions: the role of PBPK modeling. Expert Opinion on Drug Metabolism & Toxicology 14:6, pages 625-634.
Read now
Read now
Takako Furukawa, Yoichi Naritomi, Kazuhiro Tetsuka, Fumihiro Nakamori, Hiroyuki Moriguchi, Katsuhiro Yamano, Shigeyuki Terashita, Kenji Tabata & Toshio Teramura. (2014) Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys. Xenobiotica 44:3, pages 205-216.
Read now
Read now
Satya Prakash Tripathi, Anuseema Bhadauriya, Abhijeet Patil & Abhay T. Sangamwar. (2013) Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): in silico and in vitro insights. Drug Metabolism Reviews 45:2, pages 231-252.
Read now
Read now
Takako Furukawa, Katsuhiro Yamano, Yoichi Naritomi, Kohichiro Tanaka, Shigeyuki Terashita & Toshio Teramura. (2012) Method for predicting human intestinal first-pass metabolism of UGT substrate compounds. Xenobiotica 42:10, pages 980-988.
Read now
Read now
Hiroshi Komura & Masahiro Iwaki. (2011) In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences. Drug Metabolism Reviews 43:4, pages 476-498.
Read now
Read now
Chantal Guillemette, Eric Lévesque, Mario Harvey, Judith Bellemare & Vincent Menard. (2010) UGT genomic diversity: beyond gene duplication. Drug Metabolism Reviews 42:1, pages 24-44.
Read now
Read now
Articles from other publishers (74)
Shima Abdollahi, Mahdi Vajdi, Fatemeh Meshkini, Azam Ahmadi Vasmehjani, Zohreh Sadat Sangsefidi, Cain C.T. Clark & Sepideh Soltani. (2023) Resveratrol may mildly improve renal function in the general adult population: A systematic review and meta-analysis of randomized controlled clinical trials. Nutrition Research 113, pages 1-13.
Crossref
Crossref
Xin-Fang Zhai, Jing-Jing Fan, Yang Yi, Meng Zhang, Xia Yuan, Xue Qiao, Lei Liang & Min Ye. (2023) Collaborative modification strategy to develop a highly selective fluorescent probe for human UDP-glucuronosyltransferase 1A10. Chemical Engineering Journal 463, pages 142382.
Crossref
Crossref
Zhe Wang, Lili Jiang, Xiaoyu Wang, Hang Yin, Zhen Wang, Xin Lv & Yong Liu. (2022)
Cabozantinib Carries the Risk of Drug-Drug Interactions
via
Inhibition of UDPglucuronosyltransferase
(UGT) 1A9
. Current Drug Metabolism 23:11, pages 912-919.
Crossref
Crossref
Adam S. Darwich, Oliver J. Hatley, Andrés Olivares‐Morales, Farzaneh Salem, Alison Margolskee & Amin Rostami‐Hodjegan. 2022. Oral Drug Delivery for Modified Release Formulations. Oral Drug Delivery for Modified Release Formulations
65
86
.
Alan Talevi. 2022. The ADME Encyclopedia. The ADME Encyclopedia
725
732
.
Zhe Wang, Xiaoyu Wang, Zhen Wang, Yaqin Jia, Yuyi Feng, Lili Jiang, Yangliu Xia, Jun Cao & Yong Liu. (2021) In vitro inhibition of human UDP-glucuronosyltransferase (UGT) 1A1 by osimertinib, and prediction of in vivo drug-drug interactions. Toxicology Letters 348, pages 10-17.
Crossref
Crossref
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
263
292
.
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
129
167
.
Yi Kuang, Yue Chai, Lulu Xu, Zilong Wang, Lei Liang, Xue Qiao & Min Ye. (2021) Glabrone as a specific UGT1A9 probe substrate and its application in discovering the inhibitor glycycoumarin. European Journal of Pharmaceutical Sciences 161, pages 105786.
Crossref
Crossref
Rajat Sandhir, Nitin Singhal & Priyanka Garg. 2021. Mitochondrial Dysfunction and Nanotherapeutics. Mitochondrial Dysfunction and Nanotherapeutics
349
384
.
Alan Talevi. 2021. The ADME Encyclopedia. The ADME Encyclopedia
1
8
.
Wamidh H. Talib, Ahmad Riyad Alsayed, Faten Farhan & Lina T. Al Kury. (2020) Resveratrol and Tumor Microenvironment: Mechanistic Basis and Therapeutic Targets. Molecules 25:18, pages 4282.
Crossref
Crossref
Yasuharu Nakanishi, Yasuhiro Uno & Hiroshi Yamazaki. (2020) Regional distributions of UDP-glucuronosyltransferase activities toward estradiol and serotonin in the liver and small intestine of cynomolgus macaques. Drug Metabolism and Pharmacokinetics 35:4, pages 401-404.
Crossref
Crossref
Zhe Wang, Xiaoyu Wang, Yaqin Jia, Hang Yin, Yuyi Feng, Lili Jiang, Jun Cao & Yong Liu. (2020) Inhibition of human UDP‐glucuronosyltransferase enzymes by midostaurin and ruxolitinib: implications for drug–drug interactions. Biopharmaceutics & Drug Disposition 41:6, pages 231-238.
Crossref
Crossref
Abdullah Shaito, Anna Maria Posadino, Nadin Younes, Hiba Hasan, Sarah Halabi, Dalal Alhababi, Anjud Al-Mohannadi, Wael M Abdel-Rahman, Ali H. Eid, Gheyath K. Nasrallah & Gianfranco Pintus. (2020) Potential Adverse Effects of Resveratrol: A Literature Review. International Journal of Molecular Sciences 21:6, pages 2084.
Crossref
Crossref
Risto O. Juvonen, Aki T. Heikkinen, Olli Kärkkäinen, Rabia Jehangir, Juhani Huuskonen, Johanna Troberg, Hannu Raunio, Olli T. Pentikäinen & Moshe Finel. (2020) In vitro glucuronidation of 7-hydroxycoumarin derivatives in intestine and liver microsomes of Beagle dogs. European Journal of Pharmaceutical Sciences 141, pages 105118.
Crossref
Crossref
Erika Cione, Chiara La Torre, Roberto Cannataro, Maria Cristina Caroleo, Pierluigi Plastina & Luca Gallelli. (2019) Quercetin, Epigallocatechin Gallate, Curcumin, and Resveratrol: From Dietary Sources to Human MicroRNA Modulation. Molecules 25:1, pages 63.
Crossref
Crossref
Noémi-Piroska KovácsAttila AlmásiKitti GaraiMónika KuzmaSzende VanceaEmil FischerPál Perjési. (2019) Investigation of intestinal elimination and biliary excretion of ibuprofen in hyperglycemic rats. Canadian Journal of Physiology and Pharmacology 97:11, pages 1080-1089.
Crossref
Crossref
Robyn Meech, Dong Gui Hu, Ross A. McKinnon, Siti Nurul Mubarokah, Alex Z. Haines, Pramod C. Nair, Andrew Rowland & Peter I. Mackenzie. (2019) The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms. Physiological Reviews 99:2, pages 1153-1222.
Crossref
Crossref
Margherita Springer & Sofia Moco. (2019) Resveratrol and Its Human Metabolites—Effects on Metabolic Health and Obesity. Nutrients 11:1, pages 143.
Crossref
Crossref
Michael S. Little, Samantha M. Ervin, William G. Walton, Ashutosh Tripathy, Yongmei Xu, Jian Liu & Matthew R. Redinbo. (2018)
Active site flexibility revealed in crystal structures of
Parabacteroides merdae
β‐glucuronidase from the human gut microbiome
. Protein Science 27:12, pages 2010-2022.
Crossref
Crossref
Nurul Mubarokah, Julie-Ann Hulin, Peter I. Mackenzie, Ross A. McKinnon, Alex Z. Haines, Dong Gui Hu & Robyn Meech. (2018)
Cooperative Regulation of Intestinal UDP-Glucuronosyltransferases 1A8, -1A9, and 1A10 by CDX2 and HNF4
α
Is Mediated by a Novel Composite Regulatory Element
. Molecular Pharmacology 93:5, pages 541-552.
Crossref
Crossref
Risto O. Juvonen, Sanna Rauhamäki, Sami Kortet, Sanna Niinivehmas, Johanna Troberg, Aleksanteri Petsalo, Juhani Huuskonen, Hannu Raunio, Moshe Finel & Olli T. Pentikäinen. (2018) Molecular Docking-Based Design and Development of a Highly Selective Probe Substrate for UDP-glucuronosyltransferase 1A10. Molecular Pharmaceutics 15:3, pages 923-933.
Crossref
Crossref
Michael S. LittleSamuel J. PellockWilliam G. WaltonAshutosh TripathyMatthew R. Redinbo. (2017) Structural basis for the regulation of β-glucuronidase expression by human gut Enterobacteriaceae. Proceedings of the National Academy of Sciences 115:2.
Crossref
Crossref
Takanori Akazawa, Yasuo Uchida, Eisuke Miyauchi, Masanori Tachikawa, Sumio Ohtsuki & Tetsuya Terasaki. (2017) High Expression of UGT1A1/1A6 in Monkey Small Intestine: Comparison of Protein Expression Levels of Cytochromes P450, UDP-Glucuronosyltransferases, and Transporters in Small Intestine of Cynomolgus Monkey and Human. Molecular Pharmaceutics 15:1, pages 127-140.
Crossref
Crossref
Ruiya Zhang, Yonglei Cui, Yan Wang, Xiangge Tian, Lu Zheng, HaiJian Cong, Bin Wu, Xiaokui Huo, Chao Wang, BaoJing Zhang, Xiaobo Wang & Zhonghui Yu. (2017) Catechol-O-Methyltransferase and UDP-Glucuronosyltransferases in the Metabolism of Baicalein in Different Species. European Journal of Drug Metabolism and Pharmacokinetics 42:6, pages 981-992.
Crossref
Crossref
Mei Wong & Mark McAllister. 2017. Oral Formulation Roadmap from Early Drug Discovery to Development. Oral Formulation Roadmap from Early Drug Discovery to Development
9
37
.
Darja Gramec Skledar, Jan Schmidt, Anja Fic, Ivana Klopčič, Jurij Trontelj, Marija Sollner Dolenc, Moshe Finel & Lucija Peterlin Mašič. (2016) Influence of metabolism on endocrine activities of bisphenol S. Chemosphere 157, pages 152-159.
Crossref
Crossref
Dan Liu, Shuang Li, Jia-qi Qi, Da-li Meng & Yun-feng Cao. (2016) The inhibitory effects of nor-oleanane triterpenoid saponins from Stauntonia brachyanthera towards UDP-glucuronosyltransferases. Fitoterapia 112, pages 56-64.
Crossref
Crossref
Christopher R. Jones, Oliver J. D. Hatley, Anna-Lena Ungell, Constanze Hilgendorf, Sheila Annie Peters & Amin Rostami-Hodjegan. (2016) Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination. The AAPS Journal 18:3, pages 589-604.
Crossref
Crossref
Nan Zhang, Yong Liu & Hyunyoung Jeong. (2015) Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases. Scientific Reports 5:1.
Crossref
Crossref
Khalid O Alfarouk, Christian-Martin Stock, Sophie Taylor, Megan Walsh, Abdel Khalig Muddathir, Daniel Verduzco, Adil H H Bashir, Osama Y Mohammed, Gamal O Elhassan, Salvador Harguindey, Stephan J Reshkin, Muntaser E Ibrahim & Cyril Rauch. (2015) Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell International 15:1.
Crossref
Crossref
Josiane de Oliveira Cardoso, Regina Vincenzi Oliveira, Jessica Bo Li Lu & Zeruesenay Desta. (2015) In Vitro Metabolism of Montelukast by Cytochrome P450s and UDP-Glucuronosyltransferases. Drug Metabolism and Disposition 43:12, pages 1905-1916.
Crossref
Crossref
BT Gufford, JT Barr, V González‐Pérez, ME Layton, JR WhiteJrJr, NH Oberlies & MF Paine. (2015) Quantitative prediction and clinical evaluation of an unexplored herb–drug interaction mechanism in healthy volunteers. CPT: Pharmacometrics & Systems Pharmacology 4:12, pages 701-710.
Crossref
Crossref
Saeed Alqahtani & Amal Kaddoumi. (2015) Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability. Biopharmaceutics & Drug Disposition 36:9, pages 587-602.
Crossref
Crossref
Brandon T. Gufford, Gang Chen, Ana G. Vergara, Philip Lazarus, Nicholas H. Oberlies & Mary F. Paine. (2015) Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product–Drug Interaction. Drug Metabolism and Disposition 43:9, pages 1353-1359.
Crossref
Crossref
Emil FischerAttila AlmásiSztojan BojcsevTamás FischerNoémi Piroska KovácsPál Perjési. (2015) Effect of experimental diabetes and insulin replacement on intestinal metabolism and excretion of 4-nitrophenol in rats. Canadian Journal of Physiology and Pharmacology 93:6, pages 459-464.
Crossref
Crossref
Edna F. Choo, Sarah Woolsey, Kevin DeMent, Justin Ly, Kirsten Messick, Ann Qin & Ryan Takahashi. (2015) Use of Transgenic Mouse Models to Understand the Oral Disposition and Drug-Drug Interaction Potential of Cobimetinib, a MEK Inhibitor. Drug Metabolism and Disposition 43:6, pages 864-869.
Crossref
Crossref
Shingo Oda, Ryoichi Fujiwara, Yuki Kutsuno, Tatsuki Fukami, Tomoo Itoh, Tsuyoshi Yokoi & Miki Nakajima. (2015) Targeted Screen for Human UDP-Glucuronosyltransferases Inhibitors and the Evaluation of Potential Drug-Drug Interactions with Zafirlukast. Drug Metabolism and Disposition 43:6, pages 812-818.
Crossref
Crossref
Erik Sjögren, David Dahlgren, Carl Roos & Hans Lennernäs. (2015)
Human
in Vivo
Regional Intestinal Permeability: Quantitation Using Site-Specific Drug Absorption Data
. Molecular Pharmaceutics 12:6, pages 2026-2039.
Crossref
Crossref
Shingo Oda, Tatsuki Fukami, Tsuyoshi Yokoi & Miki Nakajima. (2015) A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metabolism and Pharmacokinetics 30:1, pages 30-51.
Crossref
Crossref
Yoichi Naritomi, Fumihiro Nakamori, Takako Furukawa & Kenji Tabata. (2015) Prediction of hepatic and intestinal glucuronidation using in vitro–in vivo extrapolation. Drug Metabolism and Pharmacokinetics 30:1, pages 21-29.
Crossref
Crossref
Barbara A. Wetmore, Brittany Allen, Harvey J. ClewellIIIIII, Timothy Parker, John F. Wambaugh, Lisa M. Almond, Mark A. Sochaski & Russell S. Thomas. (2014) Incorporating Population Variability and Susceptible Subpopulations into Dosimetry for High-Throughput Toxicity Testing. Toxicological Sciences 142:1, pages 210-224.
Crossref
Crossref
Brandon T. Gufford, Gang Chen, Philip Lazarus, Tyler N. Graf, Nicholas H. Oberlies & Mary F. Paine. (2014) Identification of Diet-Derived Constituents as Potent Inhibitors of Intestinal Glucuronidation. Drug Metabolism and Disposition 42:10, pages 1675-1683.
Crossref
Crossref
Irene Pereira de Sousa & Andreas Bernkop-Schnürch. (2014) Pre-systemic metabolism of orally administered drugs and strategies to overcome it. Journal of Controlled Release 192, pages 301-309.
Crossref
Crossref
Brahim Achour, Amin Rostami-Hodjegan & Jill Barber. (2014) Protein expression of various hepatic uridine 5′-diphosphate glucuronosyltransferase (UGT) enzymes and their inter-correlations: a meta-analysis. Biopharmaceutics & Drug Disposition 35:6, pages 353-361.
Crossref
Crossref
I. S. Haslam & N. L. Simmons. (2014) Expression of the ABC transport proteins MDR1 (ABCB1) and BCRP (ABCG2) in bovine rumen. Journal of Comparative Physiology B 184:5, pages 673-681.
Crossref
Crossref
Erik Sjögren, Bertil Abrahamsson, Patrick Augustijns, Dieter Becker, Michael B. Bolger, Marcus Brewster, Joachim Brouwers, Talia Flanagan, Matthew Harwood, Christian Heinen, René Holm, Hans-Paul Juretschke, Marlies Kubbinga, Anders Lindahl, Viera Lukacova, Uwe Münster, Sibylle Neuhoff, Mai Anh Nguyen, Achiel van Peer, Christos Reppas, Amin Rostami Hodjegan, Christer Tannergren, Werner Weitschies, Clive Wilson, Patricia Zane, Hans Lennernäs & Peter Langguth. (2014) In vivo methods for drug absorption – Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. European Journal of Pharmaceutical Sciences 57, pages 99-151.
Crossref
Crossref
Meiyu Wang, Jia Lu, Jiajun Li, Huixin Qi, Yedong Wang & Hongjian Zhang. (2014) Steviol glucuronidation and its potential interaction with UDP-glucuronosyltransferase 2B7 substrates. Food and Chemical Toxicology 64, pages 135-143.
Crossref
Crossref
Shingo Oda, Tatsuki Fukami, Tsuyoshi Yokoi & Miki Nakajima. (2014) Epigenetic regulation of the tissue-specific expression of human UDP-glucuronosyltransferase (UGT) 1A10. Biochemical Pharmacology 87:4, pages 660-667.
Crossref
Crossref
Fredrik H. Karlsson, Salim Bouchene, Constanze Hilgendorf, Hugues Dolgos & Sheila Annie Peters. (2013) Utility of In Vitro Systems and Preclinical Data for the Prediction of Human Intestinal First-Pass Metabolism during Drug Discovery and Preclinical Development. Drug Metabolism and Disposition 41:12, pages 2033-2046.
Crossref
Crossref
Torill Fladvad, Pål Klepstad, Mette Langaas, Ola Dale, Stein Kaasa, Augusto Caraceni & Frank Skorpen. (2013) Variability in UDP-glucuronosyltransferase genes and morphine metabolism. Pharmacogenetics and Genomics 23:3, pages 117-126.
Crossref
Crossref
Hao Xie, Shiqing Sun, Xuefang Cheng, Tingting Yan, Xiao Zheng, Feiyan Li, Qu Qi, Guangji Wang & Haiping Hao. (2013) Dysregulations of Intestinal and Colonic UDP-glucuronosyltransferases in Rats with Type 2 Diabetes. Drug Metabolism and Pharmacokinetics 28:5, pages 427-434.
Crossref
Crossref
Angela Dudda & Gert Ulrich Kuerzel. 2013. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays
1053
1094
.
M. D. Harwood, S. Neuhoff, G. L. Carlson, G. Warhurst & A. Rostami‐Hodjegan. (2012)
Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic
in vitro–in vivo
extrapolation of oral drug absorption
. Biopharmaceutics & Drug Disposition 34:1, pages 2-28.
Crossref
Crossref
Christina S. Won, Nicholas H. Oberlies & Mary F. Paine. (2012) Mechanisms underlying food–drug interactions: Inhibition of intestinal metabolism and transport. Pharmacology & Therapeutics 136:2, pages 186-201.
Crossref
Crossref
Sheila Annie Peters. 2012. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations
161
181
.
Sheila Annie Peters. 2012. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations
43
88
.
Sheila Annie Peters. 2012. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations
273
298
.
Alexander V. LyubimovDeepak K. Dalvie & Cho‐Ming Loi. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
36
.
Takafumi Akabane, Nicolas Gerst, Yoichi Naritomi, Jeffrey N. Masters & Kouichi Tamura. (2012) A Practical and Direct Comparison of Intrinsic Metabolic Clearance of Several Non-CYP Enzyme Substrates in Freshly Isolated and Cryopreserved Hepatocytes. Drug Metabolism and Pharmacokinetics 27:2, pages 181-191.
Crossref
Crossref
Takako Furukawa, Fumihiro Nakamori, Kazuhiro Tetsuka, Yoichi Naritomi, Hiroyuki Moriguchi, Katsuhiro Yamano, Shigeyuki Terashita & Toshio Teramura. (2012) Quantitative Prediction of Intestinal Glucuronidation of Drugs in Rats Using In Vitro Metabolic Clearance Data. Drug Metabolism and Pharmacokinetics 27:2, pages 171-180.
Crossref
Crossref
Yun-Feng Cao, Rong-Rong He, Jun Cao, Jian-Xing Chen, Ting Huang & Yong Liu. (2012) Drug-Drug Interactions Potential of Icariin and Its Intestinal Metabolites via Inhibition of Intestinal UDP-Glucuronosyltransferases. Evidence-Based Complementary and Alternative Medicine 2012, pages 1-8.
Crossref
Crossref
Keigo Kosaka, Norifumi Sakai, Yuya Endo, Yuga Fukuhara, Minoru Tsuda-Tsukimoto, Tatsuyuki Ohtsuka, Ichiro Kino, Tomohiko Tanimoto, Naomi Takeba, Masakatsu Takahashi & Toshiyuki Kume. (2011) Impact of Intestinal Glucuronidation on the Pharmacokinetics of Raloxifene. Drug Metabolism and Disposition 39:9, pages 1495-1502.
Crossref
Crossref
J Bellemare, M Rouleau, M Harvey, B Têtu & C Guillemette. (2009) Alternative-splicing forms of the major phase II conjugating UGT1A gene negatively regulate glucuronidation in human carcinoma cell lines. The Pharmacogenomics Journal 10:5, pages 431-441.
Crossref
Crossref
Aleksandra Galetin, Michael Gertz & J. Brian Houston. (2010) Contribution of Intestinal Cytochrome P450-Mediated Metabolism to Drug-Drug Inhibition and Induction Interactions. Drug Metabolism and Pharmacokinetics 25:1, pages 28-47.
Crossref
Crossref
Aleksandra Galetin & J. Brian Houston. 2009. Enzyme Inhibition in Drug Discovery and Development. Enzyme Inhibition in Drug Discovery and Development
315
343
.
Amin Rostami‐Hodjegan. 2009. Enzyme Inhibition in Drug Discovery and Development. Enzyme Inhibition in Drug Discovery and Development
549
568
.
Masayuki Takahashi, Takuo Washio, Norio Suzuki, Katsuhiro Igeta & Shinji Yamashita. (2009) The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans. Journal of Pharmaceutical Sciences 98:11, pages 4343-4353.
Crossref
Crossref
Helen E. Cubitt, J. Brian Houston & Aleksandra Galetin. (2009) Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug Clearance. Pharmaceutical Research 26:5, pages 1073-1083.
Crossref
Crossref
Masoud Jamei, Gemma L. Dickinson & Amin Rostami-Hodjegan. (2009) A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates. Drug Metabolism and Pharmacokinetics 24:1, pages 53-75.
Crossref
Crossref
Christopher Kohl. 2008. Drug Bioavailability. Drug Bioavailability
333
357
.
Masayuki Takahashi, Takuo Washio, Norio Suzuki, Katsuhiro Igeta, Yoshimine Fujii, Masahiro Hayashi, Yoshiyuki Shirasaka & Shinji Yamashita. (2008) Characterization of Gastrointestinal Drug Absorption in Cynomolgus Monkeys. Molecular Pharmaceutics 5:2, pages 340-348.
Crossref
Crossref
Kazuya Ishida, Shigehiro Taira, Hiroki Morishita, Yuichiro Kayano, Masato Taguchi & Yukiya Hashimoto. (2008) Stereoselective Oxidation and Glucuronidation of Carvedilol in Human Liver and Intestinal Microsomes. Biological & Pharmaceutical Bulletin 31:6, pages 1297-1300.
Crossref
Crossref